{
    "Trade/Device Name(s)": [
        "IMMULITE",
        "IMMULITE 1000 Turbo Intact PTH"
    ],
    "Submitter Information": "Diagnostic Products Corporation",
    "510(k) Number": "K053533",
    "Predicate Device Reference 510(k) Number(s)": [
        "K992105"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CEW"
    ],
    "Summary Letter Date": "February 3, 2006",
    "Summary Letter Received Date": "December 20, 2005",
    "Submission Date": "December 16, 2005",
    "Regulation Number(s)": [
        "21 CFR 862.1545"
    ],
    "Regulation Name(s)": [
        "Parathyroid hormone test system"
    ],
    "Analyte Class(es)": [
        "endocrine"
    ],
    "Analyte(s)": [
        "Intact parathyroid hormone (PTH)",
        "Parathyrin"
    ],
    "Specimen Type(s)": [
        "EDTA plasma",
        "Serum"
    ],
    "Specimen Container(s)": [
        "EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "IMMULITE",
        "IMMULITE 1000 Analyzers"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent immunometric assay"
    ],
    "Methodologies": [
        "Immunometric assay"
    ],
    "Submission Type(s)": [
        "Assay"
    ],
    "Document Summary": "FDA 510(k) summary for IMMULITE/IMMULITE 1000 Turbo Intact PTH solid-phase chemiluminescent immunometric assay for quantitative intact PTH measurement.",
    "Indications for Use Summary": "For in vitro diagnostic use with the IMMULITE and IMMULITE 1000 Analyzers for the quantitative measurement of intact parathyroid hormone (PTH) in EDTA plasma or serum, intended as an aid in the differential diagnosis of hypercalcemia and hypocalcemia and for intraoperative use.",
    "fda_folder": "Clinical Chemistry"
}